A Phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors GISTs resistant to imatinib mesylate

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2004-001605-10-IT

Enrollment

Registered

2007-03-15

Start date

2004-04-27

Completion date

Unknown

Last updated

2025-02-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic gastrointestinal stromal tumors GISTs MedDRA version: 6.1 Level: HLT Classification code 10017992

Interventions

Product Name: L01XX Product Code: PTK787/ZK222584 Pharmaceutical Form: Film-coated tablet CAS Number: 212142-18-2 Current Sponsor code: PTK787 Concentration unit: mg milligram(s) Concentration type:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Main Objective: To determine safety and tolerability and efficacy of chronic oral administration of PTK787/ZK222584 in the treatment of imatinib-resistent GISTs;Secondary Objective: ;Primary end point(s):	—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026